Can-Fite BioPharma Ltd.
CANF | TA
Overview
Corporate Details
- ISIN(s):
- IL0010944739 (+2 more)
- LEI:
- 549300ZLRH6GSBOHFZ59
- Country:
- Israel
- Address:
- PO BOX 7537, 4917000 PETACH-TIKVA
- Website:
- https://www.canfite.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Can-Fite BioPharma is an advanced clinical-stage biopharmaceutical company with integrated pharmaceutical discovery and clinical development capabilities. The company develops orally bioavailable, small-molecule drugs to treat oncology, inflammatory, and metabolic diseases. Its core platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target, as this receptor is highly expressed in pathological cells but not in normal ones. Can-Fite's pipeline features proprietary drug candidates in Phase II and Phase III clinical development that bind with high affinity to A3AR, initiating anti-inflammatory and anti-cancer effects by modulating signal transduction pathways.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Can-Fite BioPharma Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-28 17:33 |
Foreign Filer Report
Financial results for the six months ended June 30, 2025 and updates on drug de…
|
English | 339.1 KB | |
| 2025-08-28 17:33 |
Foreign Filer Report
Financial results for the six months ended June 30, 2025 and updates on drug de…
|
English | 36.8 KB | |
| 2025-07-30 16:00 |
Foreign Filer Report
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% …
|
English | 144.2 KB | |
| 2025-07-30 16:00 |
Foreign Filer Report
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% …
|
English | 36.8 KB | |
| 2025-07-29 19:10 |
Prospectus
Prospectus Filed pursuant to Rule 424(b)(4)
|
English | 455.7 KB | |
| 2025-07-29 19:10 |
Foreign Filer Report
Prospectus Filed pursuant to Rule 424(b)(4)
|
English | 36.7 KB | |
| 2025-07-29 19:07 |
Foreign Filer Report
6-K: Report of foreign issuer
|
English | 654.1 KB | |
| 2025-07-29 19:07 |
Foreign Filer Report
6-K: Report of foreign issuer
|
English | 36.7 KB | |
| 2025-07-29 01:15 |
Foreign Filer Report
Other Report or Announcement
|
English | 160.7 KB | |
| 2025-07-29 01:15 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.8 KB | |
| 2025-07-28 16:00 |
Foreign Filer Report
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment…
|
English | 146.0 KB | |
| 2025-07-28 16:00 |
Foreign Filer Report
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment…
|
English | 36.7 KB | |
| 2025-07-26 01:00 |
Registration Form
Other Report or Announcement
|
English | 2.5 MB | |
| 2025-07-26 01:00 |
Registration Form
Other Report or Announcement
|
English | 36.7 KB | |
| 2025-07-24 01:15 |
Registration Form
Other Report or Announcement
|
English | 1.8 MB |
Automate Your Workflow. Get a real-time feed of all Can-Fite BioPharma Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Can-Fite BioPharma Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
